Study: Treating Male Partners Reduces Bacterial Vaginosis Recurrence in Heterosexual Couples
New trial finds treating male partners halves bacterial vaginosis recurrence in heterosexual couples — reinfection fell from 63% to 35% over 12 weeks.
A randomized trial in Australia found that treating male sexual partners alongside women with bacterial vaginosis (BV) substantially reduced recurrence rates, suggesting sexual transmission may play a larger role in BV relapse than previously recognized. The study compared standard treatment of women alone with a combined approach in which male partners received both an oral antibiotic and a topical cream, and reported markedly lower reinfection among women whose partners were treated.
Study design and primary results
The trial enrolled 164 monogamous heterosexual couples in which the female partner had a confirmed BV diagnosis, and followed participants over a 12-week period. Couples were randomized to either woman-only treatment or combined treatment that added an oral antibiotic and topical cream for the male partner.
After the trial reached an early stop following completion by 150 couples, researchers reported a reinfection rate of 63% in the woman-only group versus 35% among women whose male partners were treated. Investigators concluded that partner treatment significantly reduced BV recurrence during the follow-up window.
Evidence supporting sexual transmission of BV-associated bacteria
The study adds to accumulating evidence that BV-associated bacteria can be found in male genital sites, including penile skin and the urethra, and that these reservoirs may seed reinfection. Experts note that while BV has long been linked with sexual activity, it has not been formally classified as a sexually transmitted infection because it can rarely appear in sexually inactive individuals and men typically remain asymptomatic.
Gale Burstein, MD, MPH, FAAP, said the trial’s results provide robust evidence that BV-associated organisms can be transmitted between sexual partners and that treating asymptomatic male partners could help prevent reinfection. The researchers argued that partner treatment should be viewed as a shared responsibility rather than solely the woman’s clinical problem.
Why BV remains unclassified as an STI despite new data
Clinicians caution that the trial does not yet change how BV is defined in clinical guidelines. Aparna Sridhar, MD, an associate clinical professor of obstetrics and gynecology, said the findings are important but insufficient to reclassify BV as an STI, particularly because BV can occur in people who have never had sexual intercourse.
Previous studies from the 1980s and 1990s that attempted partner treatment did not show benefit and helped shape the prevailing view that BV was not sexually transmitted. Those earlier trials, however, treated male partners only with oral antibiotics and did not include topical therapy, a limitation that the current trial sought to address.
Limitations and questions about generalizability
The trial has notable limitations that temper broad application of its findings. It enrolled only monogamous heterosexual couples, so results may not apply to women with multiple partners or to same-sex partnerships. The study population was largely drawn from Western Pacific and European-born participants in Australia, raising questions about how the intervention performs across different regions and ethnic groups.
Researchers also cautioned that the follow-up period was limited to 12 weeks, and longer-term effectiveness and potential antimicrobial resistance were not assessed in this report. Clinicians will want additional data on durability of benefit and safety before altering widespread practice.
Clinical implications and recommendations under consideration
Practicing clinicians are likely to weigh the new data alongside guideline processes from professional bodies. Some providers may begin discussing partner treatment with patients in heterosexual relationships who experience recurrent BV, especially when previous courses of therapy have failed. The trial investigators have produced resources to inform clinicians and to help patients discuss partner treatment with their sexual partners.
Major professional organizations, including obstetrics and gynecology societies, have not yet issued formal recommendations to endorse routine partner treatment for BV. Experts emphasize that patients should be counseled about current uncertainties, the potential benefits observed in this trial, and limitations related to population and follow-up.
This study advances understanding of why many women experience repeated episodes of bacterial vaginosis and offers a practical intervention that reduced short-term recurrence in the trial cohort. Further research is needed to confirm effectiveness across diverse populations, to evaluate longer-term outcomes and resistance risks, and to determine whether guideline committees will recommend partner treatment as part of standard BV management.
